Page 73 - MEMORIA ANUAL 2021

MEMORIA ANUAL 2021 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
63rd Annual Meeting of the American-Society-of-Hematology (ASH). Georgia, Dec 11-14, 2021.
Simoes CP, Chillón C, Martínez-Cuadrón D, Calasanz MJ, Vidriales MB, Vázquez I, Her- nández-Ruano M, Ariceta B, Burgos L, Alignani D, Sarai S, Villar S, Prósper F, Ayala R, Martínez-López J, Bergua Burgués JM, Vives S, Pérez-Simón JA, García-Fortes M, Gon- zález M, San-Miguel J, Sanz MA, Montesinos P .
• Circulating tumor cells (CTC) are the most relevant diagnostic biomarker in trans- plant eligible multiple myeloma (MM).
26th Congress of the European-Hematology-Association (EHA). EHA2021 VIRTUAL, Jun 9-17.
Garcés JJ, Cedena MT, Puig N, Burgos L, Pérez JJ, Cordón L, Flores-Montero J, Sanoja- Flores L, Oriol A, Blanchard MJ, Ríos R, Martín J, Martínez-Martínez R, Bargay J, Sureda A, De La Rubia J, Hernández MT, Rodríguez-Otero P, Orfao A, Mateos MV, Martínez-López J, Rosiñol L, Bladé J, San-Miguel JF, Paiva B .
• A machine learning model based on tumor and immune biomarkers to predict undetect- able measurable residual disease (MRD) in transplant-eligible multiple myeloma (MM). Clinical Lymphoma Myeloma & Leukemia. 2021;21:S35-S.
Guerrero C, Puig N, Cedena MT, Goicoechea I, Pérez C, Garcés JJ, Botta C, Calasanz MJ, Gutiérrez NC, Martín-Ramos ML, Oriol A, Ríos R, Hernández M, Martínez R, Bargay J, De Arriba F, Palomera L, González AP, Mosquera Orgueira A, González MS, Martínez-López J, Lahuerta JJ, Rosiñol L, Bladé Creixenti J, Mateos MV, San-Miguel J, Paiva B .
• A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable Measurable Residual Disease (MRD) in Transplant-Eligible Multiple My- eloma (MM).
63rd Annual Meeting of the American-Society-of-Hematology (ASH). Georgia, Dec 11-14, 2021.
Guerrero C, Puig N, Cedena MT, Goicoechea I, Pérez C, Garcés JJ, Botta C, Calasanz MJ, Gutiérrez NC, Martín-Ramos ML, Oriol A, Ríos R, Hernández M, Martínez R, Bargay J, De Arriba F, Palomera L, González AP, Mosquera Orgueira A, González MS, Martínez-López J, Lahuerta JJ, Rosiñol L, Bladé Creixenti J, Mateos MV, San-Miguel J, Paiva B .
• Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial.
63rd Annual Meeting of the American-Society-of-Hematology (ASH). Georgia, Dec 11-14, 2021.
73